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UMBILICAL CORD BLOOD BANKING IN THE WORLDWIDE 
HEMATOPOIETIC STEM CELL TRANSPLANTATION SYSTEM: 
PERSPECTIVES FOR UKRAINE
T.O. Kalynychenko
State Institution “Institute of Hematology and Transfusiology of the National Academy of Medical 
Sciences of Ukraine”, Kyiv 04060, Ukraine
Significant progress in the promotion of procedural technologies associated with the transplantation of hematopoietic stem cells 
caused a rapid increase in activity. The exchange of hematopoietic stem cells for unrelated donor transplantations is now much 
easier due to the relevant international professional structures and organizations established to support cooperation and standard 
setting, as well as rules for the functioning of both national donor registries and cord blood banks. These processes are increasing 
every year and are contributing to the outpacing rates of development in this area. Products within their country should be regulated 
by the competent government authorities. This study analyzes the work of international and national levels of support for transplan-
tation activity in the field of unrelated hematopoietic stem cell transplantation, the standardization order of technologies, as well 
as data that justify the need to create a network of donated umbilical cord blood banks in Ukraine as a factor in the development 
of allogeneic transplantation. This will promote the accessibility of international standards for the treatment of serious diseases 
for Ukrainian citizens.
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INTRODUCTION
Hematopoietic cells are perhaps the only type 
of adult stem cells that has firmly become the part of the 
arsenal of medical care for life-threatening diseases.
Today, hematopoietic stem cell transplantation 
(HSCT) from bone marrow (BM), stimulated peripheral 
blood (PB), and umbilical cord blood (UCB) Is estimat-
ed as an effective way of curing for more than 80 seri-
ous diseases associated with hematopoietic system 
disorders. HSCT has gone through a half-century 
of development from experiment to the recognized 
successful medical technology [1–3].
In recent years, due to significant advances in pro-
cedural advancement technologies, the growth rate 
of the absolute quantitative indicators of HSCT has 
been steadily increasing, while the proportions of the 
using of donor types are constantly changing. Accord-
ing to The Worldwide Network of Blood and Marrow 
Transplantation (WBMT), the dominance of allogeneic 
variants over autologous transplants is the current trend 
of the global growth [4]. So, in comparison with 2006, 
the overall increase for 2012 was 46%. At the same time, 
the number of the allogeneic transplants increased 
by 57%, while the raise in the autologous transplantation 
was at the level of 38%. A global analysis of the relative 
transplant activity indicators showed their heteroge-
neity with a significant advantage in favor of countries 
with a high gross domestic product per person, which 
is directly related to high expenditure volumes for health 
protection. In addition, the availability of an infrastruc-
ture in the form of a national hematopoietic stem cell 
(HSC) registries with a wide list of donors, large cord 
blood banks (CBBs), and transplant centers with pro-
fessional cohesive teams is very important.
Unfortunately, these positive processes cover not all 
continents and regions. The widening gap in the indica-
tors of transplant activity among countries with different 
economic development takes place, which, in its turn, 
raises the question of the need to strive for unification 
and price reducing medical technologies in this area.
WORLD SUPPORTING EXPERIENCE 
IN THE FIELD OF UNRELATED 
HEMATOPOIETIC STEM CELL 
TRANSPLANT ACTIVITIES
The guiding principles of the World Health Organiza-
tion (WHO) declare the transplantation of organs, cells 
and tissues to be a global task, with the collection of ac-
tivity data being one of the prime prerequisites [4–6].
Despite the rapid growth in the number of the 
transplantations, their rates for 10 million people in dif-
ferent regions of the world vary considerably (alloge-
neic transplants from 0.4 to 506) [2, 7]. At what even 
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in areas with a large number of transplantations, these 
numbers are far from oversaturation. For example, 
in the USA only a third of those patients who needed 
unrelated transplantation had a preliminary search for 
a donor in the National Marrow Donor Registry [7].
Thus, the question of how best to organize trans-
plant activity is still open. A number of international 
non-governmental and non-profit organizations are 
engaged in scientific and practical issues in this field.
The WBMT, which has formal relations with WHO, 
has undertaken the mission of promoting best prac-
tices in HSCT area, as well as stem cell donation and 
cellular therapy. Its goal is to participate in scientific and 
educational activities and undertakings exclusively [8].
At the national level, government agencies are en-
gaged in the development of a transplant system. They 
take care of creating and supporting the operation 
of the infrastructure to ensure the healthcare activities 
for organ and tissue transplantation.
One of the most important components of such 
a country’s infrastructure in the HSCT sphere is the 
national donor HSC registries that act as information 
databases and containing data on the voluntary donors 
(individual code, personal data, human leukocyte an-
tigen (HLA) phenotype, information on their condition 
health at the time of entry into the registry database), 
and also include the data on the cryopreserved UCB 
units in the CBBs for unrelated transplantations.
A registry functions as a hub between different 
entities involved in the transplant process. The diffe-
rent entities connected to each other in different ways, 
depending on the country and the roles the registry 
chooses to take on [9].
One of the main voluntary organizations is The 
World Marrow Donor Association (WMDA). This is rep-
resentative of blood stem cell donor registries, CBBs, 
other organizations and individuals with an interest 
in blood stem cell transplantation. According to its 
standards, the registry is “an organization responsible 
for coordinating of the search hematopoietic progeni-
tor cells from donors (including cord blood) unrelated 
to the potential recipient”.
At the urging of the WMDA, the HSC registries should 
be a resource of information on the regulatory rules of the 
countries in which they operate, as well as information 
on national and international partners [10]. Such regis-
tries have existed for more than 25 years. Today, most 
of them are united by The Bone Marrow Donors World-
wide (BMDW) as an international service [11]. The BMDW 
creates, provides, maintains and optimizes an electronic 
data bank with centralized data on HLA phenotypes and 
other relevant stem cell donor data from volunteers and 
cryopreserved UCB products and makes them available 
for search in the interests of the particular recipient, and 
does other related activities. Since January 2017 BMDW 
has become a service of the WMDA [11].
In turn, WMDA, which has been operating since 
1994, has grown into a global association, representing 
donor registries, CBBs, donor centers, and transplant 
hospitals from 52 different countries [9]. Due to the 
fact that approximately 46% of HSC products cross 
borders, the goal of unrelated transplantation for the 
exchange cooperation between international registries 
is the WMDA mission [10, 12].
According to various sources, one in 1500 potential 
HSC donors becomes real. If the preliminary search yields 
about 10 thousand variants, then this is a good result for 
the prospect of obtaining the highest degree of compat-
ibility. When restricting the list of 20 individuals, the search 
can be lengthy and ineffective. The high cost of searching 
and activating donors in the foreign registries makes the 
transplantation almost impossible for the ordinary citizens 
of the countries that are not in the global donor network.
Allowing to the WMDA standards [9], the cell col-
lection center must be independent of the transplant 
center, both territorially and legally. The donor has the 
right to refuse a survey and donation at any stage with-
out explaining the reason, which much slows down the 
selection and testing. In the early post-donation period, 
the donor remains under medical supervision of the 
cell collection center. His Registry carries out further 
medical care and monitoring of his health. As for related 
donors, the issues connected to their servicing have not 
been completely settled. A potential conflict of interest 
is the possible participation of the same team in the 
observation of both the donor and the recipient in the 
case of the related transplant [13]. Attention is paid 
to this issue in recent changes to international stan-
dards [14]. Other issues related to the standardization 
of donor health assessment, observation and medical 
and psychological assistance after donation, in accor-
dance with the help of unrelated donors under existing 
procedures, as well as the transfer to centralized donor 
monitoring registries, are in a state of active discussion.
NetCord Foundation was founded in 1997 as a non-
profit organization and an international Eurocord arm 
for the purpose of promoting high-quality banking and 
clinical use of UCB for allogeneic HSCT through the on-
line Virtual Office. This is a network of non-commercial 
public UCB banks in Europe, the United States, Israel, 
Japan, and Australia. It covered more than 50% of the 
world’s non-commercial UCB banks, which have already 
provided more than 10 thousand transplants for adults 
and children. In 2007, The WMDA Cord Blood Working 
Group (WMDA CBWG) was established to collect and 
exchange information on cord blood registers and deve-
lopment of guidelines for international CBBs exchange 
for transplant safety [15]. According to the data of the 
WMDA CBWG, one of the difficulties during the decade 
was the duplication of lists in different services. So, until 
recently, the search in such systems as NetCord Virtual 
Office and the National Marrow Donor Program (NMDP) 
(US) Center for Cord Blood was interchangeable [15]. 
To date, since January 2017 this problem has been re-
solved by combining BMDW, WMDA and NetCord into 
a single organization. Since that time, according to the 
declaration, the NetCord working group will continue 
to work with the aim of supporting international exchange 
of cord blood units and harmonization of the world prac-
tice of bank storage [16].
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Nowadays, UCB units can be quickly searched 
using a global computerized system that contains 
accredited banks from around the world. Search cor-
responds to WMDA guidelines.
Thus, today BMDW is the primary source of all HSC 
donors and cord blood units globally, and its holds over 
30 million donors and over 700 thousand cord blood 
units from 98 registries and CBBs from 54 countries [11].
HSC SOURCES FOR TRANSPLANTATION
The use of BM as a HSC graft has more than 50 years 
of history [17, 18]. During the period following the an-
nouncement of E. Donnall Thomas et al. (1975) about 
the first successes of such treatment of patients in the 
acute leukemia final stage, this source has been widely 
recognized as an effective immune and hematopoietic 
regenerator for serious diseases. Deficiency of donors, 
when it is necessary to maintain a high degree of histo-
compatibility of the donor-recipient pair, and also the 
invasiveness of the collection procedure, which is con-
ducted under general anesthesia, stimulated an active 
search for new HSC sources. The procedure has com-
plicating risks, including: the development of anemia, 
hypovolemia caused by large volumes of BM and blood 
extraction (in total up to 1500 liters depending on the 
weight of the donor), pain at the extraction site, bleed-
ing, edema or nerve compression, perforation of the 
pelvic cavity or internal vessels, life-threatening cardiac 
or respiratory disorders, allergic reactions associated 
with general anesthesia [10, 19].
Another source — peripheral blood stem cells (PBSC), 
which today amounts to about 70% of all donations in un-
related conditions, also has a number of negative features 
associated primarily with the need to stimulate the ejec-
tion of stem cells into the PB. This is expressed in bone 
pain, nausea, vomiting, enlarged spleen, until it ruptures, 
insomnia, the appearance of flu-like symptoms, muscle 
pain. In addition, there is a danger of reactions at the 
venipuncture point, development of symptomatic citrate 
hypovolemia and hypocalcemia, and thrombocytopenia 
[10, 20–22]. Further research on the risks of development 
of early and late complications in PBSC donors continue, 
neoplastic processes including.
The general picture of the complications of donors 
confirms the need to apply strict criteria for the medical 
evaluation of candidates’ suitability.
The UCB is an alternative to the adult donor hema-
topoietic tissue (BM or PBSC) for recipients who re-
quire transplantation in the absence of suitable donors.
The fact of HSC circulation in newborn PB was de-
tected in the 80th years of the twentieth century [23]. 
UCB early hematopoietic precursors have a number 
of ontogenetically determined characteristics, among 
which: increased proliferative potential relative to other 
adult hemopoietic tissue sources, as well as prolonged 
cell cycle, cellular signaling features, increased recep-
tor sensitivity, ability to the autocrine growth factor 
producing [24].
Several first CBBs were established in the United 
States and Europe in the early 1990s [17]. After the first 
effective transplantation [25, 26], the number of such 
banks, as well as the using of stem cells from this source, 
has been increasing every year around the world [26–29]. 
Many studies have found that the frequency and degree 
of immune conflict in the graft-versus-host-disease form 
in case of UCB application are significantly lower than 
after BM transplantation [30–33]. In addition to the less 
stringent requirements for HLA compliance [34], the re-
cipients of allogeneic UCB cells do not show an increased 
risk of the tumor relapse [28]. Presupposition for the for-
mation of immunological tolerance is the neonatal nature 
of cells, including the absence of previous immunizations 
and activation of the lymphocytes by infectious agents. In-
creased (relative to the adult hematopoietic tissue donors) 
content of the non-activated immature lymphocytes, and 
the suppressor cells and a reduced monocyte amount 
with structures that determine their functional activity 
in intercellular immune responses (antigen-presenting 
structures, immune adhesion receptors, and others) are 
considered as features of the effector cells population 
composition. The disproportion of the mediator produc-
tion, the sensitivity to them, and reduced cytotoxic reac-
tivity are also signs of the functional immaturity of these 
immunocompetent cells [35, 36]. A major advantage in the 
use of cord blood is the possibility of having a frozen unit 
in the transplant center before the start of the conditioning 
regimen for the recipient [15].
To date, they are successfully used in the treatment 
of hematological, oncologic and other diseases (acute 
and chronic leukemia, myelodysplastic syndrome, 
congenital anemia (Fanconi anemia), solid tumors, 
hemoglobinopathies, severe combined immunodefi-
ciencies, congenital metabolic abnormalities, autoim-
mune diseases). The spectrum of diseases is constantly 
expanding [37–39]. But, according to WBMT data, about 
70% of all cases of UCB use as the source of allogeneic 
transplantation were in patients with leukemia, 16% — for 
non-cancerous diseases, 10% — for lymphoproliferative 
disorders, and only 1% — for solid tumors [4]. According 
to the NMDP (US) in 2010, 22% of allogeneic unrelated 
transplantations were carried out due to the use of the 
UCB itself. At the same time in children’s practice such 
transplantation is more effective than transplantation 
from the PBSC donors, therefore they were used more 
often [40]. Thus, the development of UCB transplantation 
is the reason for the rapid growth of allogeneic unrelated 
transplantation in many ways.
According to E. Gluckman data (2014), about 
30 thousand UCB units distributed worldwide for adults 
and children with severe hematological diseases [26]. 
With increasing practice of performed UCB transplan-
tation, the unit selection criteria become more perfect. 
This contributes to the globalization of cooperation [41].
STANDARDIZATION IN THE FIELD 
RELATED TO THE UMBILICAL CORD 
BLOOD HEMOPOETIC STEM CELLS 
TRANSPLANTATION TECHNOLOGIES
The need to develop international standards for 
collection, processing, testing, banking, selection and 
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release implementation manifested itself against the 
backdrop of the UCB transplantation growing role and 
the international exchange of its samples. Such stan-
dards were established by NetCord in partnership with 
the Foundation for the Accreditation of Cellular Therapy 
(FACT). Leading organizations in the field of transplanta-
tion have adopted these rules since 2001. These include 
the European Group for Blood and Marrow Transplanta-
tion (EBMT), American Society for Blood and Marrow 
Transplantation (ASBMT), International Society for 
Cellular Therapy (ISCT), WMDA, Joint Accreditation 
Committee of ISCT-Europe and EBMT (JACIE), Span-
ish National Transplant Organization (SNTO), Canadian 
Blood and Marrow Transplant Group (CBMTG).
Compliance with these standards for quality assur-
ance, validation and efficiency is the basis for inspection 
in a formal accreditation procedure, taking into account 
the rules of good manufacturing practices of the regulatory 
authorities of the country in which the cell bank is located.
At the same time, developments in the direction 
of the processing procedure improving, as well as the 
characteristics of the material, continue today, given 
the imperfection of the sample quality, even in the 
accredited banks. This is due to significant variability 
and low levels of the cell content, as well as the level 
of their viability indices.
The development of knowledge in this area leads 
to the fact that new editions of the Standards are pub-
lished approximately every three years. This allows 
them to comply with the latest developments and the 
requirements of high-quality banking [42].
Today there is the Sixth Edition NetCord-Fact Inter-
national Standards for Cord Blood Collection, Bank-
ing, and Release for Administration [43]. In addition, 
the current standards of The American Association 
of Blood Banks (AABB) form the basis of its accredita-
tion program [16]. Alliance for Harmonization of Cel-
lular Therapy Accreditation (AHCTA) with its members 
also promotes quality in the specified field [44].
Thus, the harmonization of standards and the promo-
tion of high-quality UCB units at the international level 
is due to the accreditation programs offered by WMDA, 
Netcord Foundation in cooperation with FACT and the 
AABB, which are members of the AHCTA [15]. Each 
of these programs regulates various aspects of UCB 
unrelated transplantation — from issues related to UCB 
banking and its release to focusing on registry operations.
SOME ISSUES OF PROVIDING 
UNRELATED TRANSPLANTS WITH UCB 
SAMPLES
The provision of unrelated transplants with UCB HCS 
samples around the world is being done through non-
profit donor banks that are part of their international net-
works [15, 27, 29]. Most of the donor CBBs are in close 
connection with their national HSC registries. They 
enter international search systems through registration 
of the samples in a national database. The smaller part 
of banks are independent of the national registries, their 
databases either enter into international listings directly 
or operate locally only [15, 45]. The transplant center 
receives extended information when sending a request 
for UCB samples to the system registry. The searching 
for the UCB unit provides fewer steps than for adult 
donor stem cells, because it is fully tested and all the 
necessary characteristics are provided already at the 
stage of including the unit in the search list. Due to the 
fact that the process does not require a clinical donor 
survey, in contrast to the processes in the collection 
of BM and PBSC, an emergency order can be performed 
in 1–2 days. Usually, it is 3–4 days after the notice. If ad-
ditional viability tests or colony formation capacity are 
required, this period lasts up to 15 days [15].
There are no ethical or moral prejudices in connec-
tion with UCB banking. The units can be stored in the 
cryopreserved state for at least 20 years without harm 
to the viability of the cells [17]. The lack of a cell dose 
for the adult recipients is most likely a problem that 
is solved by conducting additional studies on double 
UCB transplantation. This method is especially popular 
in USA because of the cases of increased weight among 
the recipients. Also, the use of the reduced-intensity 
conditioning regimens for the transplantation in elderly 
patients reduces the request [17, 46, 47].
In fact, the financing and the targeted purpose for the 
use of banks they are divided into two categories: public 
and private. Public banks keep the UCB units for use in al-
logeneic unrelated transplantation programs and some 
limited types of research, while private banks focus on au-
tologous or related applications. Family-directed banking 
can be useful for the families in whom an expected child 
has relatives who need the hematopoietic tissue transplant 
[48]. Some countries have public or private funding for 
storing the UCB units specifically for the families in which 
there is such a need, called “hybrid banking” [49, 50]. 
At the same time, the functioning of the public and private 
banks raises ethical and legal issues. The inadmissibility 
of the commercialization of the human body, control and 
equitable access to medical services are among the main 
problems [51–55]. Unconditional priority of altruistic do-
nation of the UCB for interests of society over autologous 
private storage should be combined with detailed, accu-
rate and timely information for the parents that takes into 
account all the pros and cons of these types of banking. 
Family members should receive detailed information about 
the therapeutic potential of the material and the realistic 
expectations of its use. It is necessary to realize that the 
expansion of private banks is a significant problem for the 
functioning of public volunteer banks, and, conversely, 
a generous gift in the form of donation can save the life 
of a needy person and does not have negative conse-
quences for the donor [48, 56].
A LOOK AT THE ADVANTAGES 
AND PROSPECTS OF UCB BANKING 
IN THE CONTEXT OF THE HSC 
TRANSPLANT SYSTEM OF UKRAINE
According to the WHO definition, transplantation 
is an important global task. Such treatment should 
be perceived as a generally accessible “standard 
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of care”, not limited to the affluent countries or individuals 
[1, 5]. In this regard, the WHO guiding principles declare: 
the transplant regulation on a national level is a govern-
mental responsibility. Considering that Ukraine has been 
a permanent member of WHO since 1948, the principles 
and international legal re commendations of this organi-
zation are binding for our country both at the legislative 
level and in the practical implementation plane.
In the opinion of Dr Luc Noël in charge of transplanta-
tion at WHO and a bioethics consultant at WHO Dr Domi-
nique Martin: “The pursuit of national self-sufficiency 
in human material for transplantation is the collective 
responsibility of all citizens, inasmuch as they are neces-
sary participants in the prevention and management of all 
diseases leading to the need for transplantation” [57].
It should be emphasized that HSCT is a vivid example 
of costly specialized medical care. In this regard, its 
widespread use was limited to high-income countries 
until recently. However, recently the situation has 
changed somewhat [1, 58]. The number of transplan-
tations has increased worldwide, including through 
the use of an alternative donor material: HLA-matched 
unrelated donors and HLA-matched UCB cells, as well 
as increased use of mobilized stem hemopoietic cells 
of the PB [59]. In addition, such changes are due 
to the spread of transplantation technologies with the 
use of the allografts for elderly recipients against the 
background of successful clinical trials in such direction 
as conditioning with reduced intensity mode, as well 
as the use of either double HLA-mismatched UCB grafts 
or related HLA-haploidentical BM material [60–62].
Unfortunately, in Ukraine, with the existence of trans-
plant centers with highly qualified teams, the introduc-
tion of unrelated transplantations to those patients who 
do not have an HLA-compatible donor-relative remains 
the biggest problem. Today, the high cost of search-
ing for and activating donors in foreign registries for 
countries such as Ukraine that are not members of the 
WMDA makes transplantation inaccessible for most 
Ukrainian patients. In addition, the problem is the lack 
of a distinct legal regulation in this area.
According to economic and social indicators, profit-
able and realistic in the conditions of Ukraine through the 
creation of HSCT reserves is the introduction of the donor 
CBBs system for public use, with their state ownership. 
The reason for this conclusion, among other things, is the 
fact that this material is usually subject to disposal after 
childbirth along with the whole fetoplacental complex. 
The state’s responsibility is to ensure the operation 
of such banks, to promote high unified quality of the prod-
uct through international accreditation and standardiza-
tion, with the guarantee of the entry of the national banks 
into international search systems through membership 
in the association of non-profit UCB banks. Alternatively, 
the introduction of a transitional model of hybrid banking 
on the basis of family banks, which already exist today 
in the field of private medicine in Ukraine, can serve 
as a matter for discussion. Storage of UCB units for al-
logeneic transplantation in such banks is possible only 
when international standardization of samples is per-
formed. After restoring economic indicators, a model 
of a state bank with partial preservation of samples for 
family use would be useful for Ukraine, provided that they 
are available to patients who are not related to the donor 
family. Such banks today have priority in some states [48, 
56, 63]. Therefore, the creation of a network of donor 
CBBs in Ukraine is quite feasible, taking into account 
the experience and development of specia lized research 
institutes of our country in this direction.
Practice shows that a thorough analysis of the 
experience of transplantation failures and successes 
promotes progress in this area of activity [2]. There are 
all prerequisites of historical, professional and economic 
nature for the development of the transplantation system 
of hematopoietic tissue in Ukraine. Thus, the scientific 
literature of the 70–80s of the 20th century covers the 
history of transplantation in our country [64–66]. These 
data, most likely, unfortunately, were not taken into ac-
count in a global analysis of all transplantation activities 
conducted recently for the WBMT [2]. In addition, Ukraine 
has strong scientific traditions and schools in the field 
of cryopreservation of hemopoietic tissue, including the 
experience of creation and functioning of cryobanks [67, 
68]. Preconditions of an economic nature allow us to hope 
for Ukraine’s exit from the cohort of countries with low 
macroeconomic indicators. Although the gross national 
income per person in Ukraine still remains very low due 
to various reasons and accounts for only 20% of the av-
erage for the EU, the economy shows the desired signs 
of recovery [69]. The cost of providing samples at the 
national level and the proper degree of self-sufficiency 
in this sense requires careful calculations, but it is al-
ready clear that the cost price of such a sample for the 
Ukrainian consumer will be significantly lower compared 
to the international exchange of samples originating from 
countries with highly developed economies. Although 
it should be borne in mind that the inclusion of the bank 
in the international exchange of samples contributes 
to their economic profitability [70]. In general, the low-
temperature banks of donor UCB hematopoietic tissue 
are a real chance of obtaining a non-related graft, primar-
ily for use in a hematology clinic.
CONCLUSION
Thus, the problem of providing transplant centers 
with sufficient and suitable stocks for clinical use is be-
ing solved by creating a register of prospective donors 
of the BM or PBSC, as well as the UCB cryobanks. 
Given the financial feasibility, the existing advantages 
of the cord blood over other sources of HSC, a network 
of donor cryobanks with state ownership and a na-
tional registry of HLA-type units is necessary for the 
establishment in Ukraine. Creation of hybrid models 
of banks, including both samples for private storage, 
and units donated for public needs, is a problem for 
discussion. Bank regulation should be carried out 
based on public information discussion within at-
tracting a wide range of specialists with giving priority 
to the public interest. This will contribute, first, to the 
correct national regulation of activities in this area, and 
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second, to the process of international accreditation. 
In general, the introduction of the method into clinical 
practice depends entirely on the state care and financ-
ing of the program for hemopoietic cell transplantation.
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